Tags

Type your tag names separated by a space and hit enter

[Detralex-phlebosclerosing treatment. Results of the national multicenter follow up programme VEIN ACT PROLONGED-C1].
Angiol Sosud Khir. 2018; 24(1):102-106.AS

Abstract

Presented herein are the results of the observational follow up study programme dedicated to the assessment of appropriate use of adjuvant therapy with Detralex while carrying out phlebosclerosing treatment in patients suffering from dilated intradermal veins (clinical class C1 according to the CEAP classification). A conclusion was drawn that administration of Detralex for 60 days decreased the incidence rate of typical undesirable side events after phlebosclerosing therapy, thus making the use of this drug appropriate in routine clinical practice.

Authors+Show Affiliations

Department of Faculty Surgery No 2, Russian National Research Medical University named after N.I. Pirogov, Moscow, Russia.Department of Faculty Surgery No 2, Russian National Research Medical University named after N.I. Pirogov, Moscow, Russia.Department of Faculty Surgery No 2, Russian National Research Medical University named after N.I. Pirogov, Moscow, Russia.

Pub Type(s)

Journal Article
Observational Study

Language

rus

PubMed ID

29688201

Citation

Bogachev, V Iu, et al. "[Detralex-phlebosclerosing Treatment. Results of the National Multicenter Follow Up Programme VEIN ACT PROLONGED-C1]." Angiologiia I Sosudistaia Khirurgiia = Angiology and Vascular Surgery, vol. 24, no. 1, 2018, pp. 102-106.
Bogachev VI, Boldin BV, Turkin PI. [Detralex-phlebosclerosing treatment. Results of the national multicenter follow up programme VEIN ACT PROLONGED-C1]. Angiol Sosud Khir. 2018;24(1):102-106.
Bogachev, V. I., Boldin, B. V., & Turkin, P. I. (2018). [Detralex-phlebosclerosing treatment. Results of the national multicenter follow up programme VEIN ACT PROLONGED-C1]. Angiologiia I Sosudistaia Khirurgiia = Angiology and Vascular Surgery, 24(1), 102-106.
Bogachev VI, Boldin BV, Turkin PI. [Detralex-phlebosclerosing Treatment. Results of the National Multicenter Follow Up Programme VEIN ACT PROLONGED-C1]. Angiol Sosud Khir. 2018;24(1):102-106. PubMed PMID: 29688201.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Detralex-phlebosclerosing treatment. Results of the national multicenter follow up programme VEIN ACT PROLONGED-C1]. AU - Bogachev,V Iu, AU - Boldin,B V, AU - Turkin,P Iu, PY - 2018/4/25/entrez PY - 2018/4/25/pubmed PY - 2018/6/6/medline SP - 102 EP - 106 JF - Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery JO - Angiol Sosud Khir VL - 24 IS - 1 N2 - Presented herein are the results of the observational follow up study programme dedicated to the assessment of appropriate use of adjuvant therapy with Detralex while carrying out phlebosclerosing treatment in patients suffering from dilated intradermal veins (clinical class C1 according to the CEAP classification). A conclusion was drawn that administration of Detralex for 60 days decreased the incidence rate of typical undesirable side events after phlebosclerosing therapy, thus making the use of this drug appropriate in routine clinical practice. SN - 1027-6661 UR - https://www.unboundmedicine.com/medline/citation/29688201/[Detralex_phlebosclerosing_treatment__Results_of_the_national_multicenter_follow_up_programme_VEIN_ACT_PROLONGED_C1]_ DB - PRIME DP - Unbound Medicine ER -